Medicines Company's Angiomax Shows Improved Outcomes in Heart Attack Patients
Posted on: Monday, 31 March 2008, 09:01 CDT
The Medicines Company has announced that Angiomax resulted in improved net adverse clinical outcomes and reduced the risk of major bleeding despite the sex, age, diabetes status or renal function of heart attack patients compared to a more complex treatment regimen 30 days following primary angioplasty.
These new findings are consistent with overall results from the Horizons-AMI trial that demonstrate treatment with Angiomax resulted in superior net clinical outcomes and fewer cardiac deaths when compared to unfractionated heparin (UFH) plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in patients presenting with ST-segment elevation myocardial infarction (STEMI), the most severe form of heart attack. Reduced bleeding has been associated with greater long-term survival in other studies in angioplasty patients.
In the overall trial of 3,602 patients, Angiomax significantly improved net clinical adverse events by 24%, significantly reduced rates of major bleeding by 40%, demonstrated comparable rates of major adverse cardiac events, and significantly reduced the incidence of cardiac-related mortality by 38% when compared to the more complex regimen of UFH plus GPI 30 days following primary angioplasty.
John Kelley, president and COO of The Medicines Company, said: "These new data from Horizons-AMI add to the wealth of clinical experience that shows Angiomax consistently improves outcomes across the entire spectrum of risk in patients undergoing percutaneous coronary intervention. Given these results, we anticipate greater uptake of Angiomax by physicians worldwide."
Source: Datamonitor
Related Articles
- Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
- GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
- EarlySense Receives FDA Clearance for Its Contact-Free Patient's Clinical Status Monitor
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- Pivotal Phase III Trial Showed PROMACTA(R) (Eltrombopag Olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
- RxHub Provides Access to Critical ePrescribing Patient Decision Support Information for the Majority of Commercially Covered Lives Within the United States
- Angiomax Reduces Bleeding in Heart Cases
- Trasylol (Aprotinin Injection) Reduced Bleeding and Transfusion Requirements in Patients on Clopidogrel Who Required Coronary Artery Bypass Graft (CABG) Surgery
- Journal of Clinical Oncology Publishes Significant Anti-Tumor Activity of Tumor Necrosis Therapy for Treating Patients With Advanced Lung Cancer
- Trasylol(R) (Aprotinin Injection) Reduced Bleeding in Patients Receiving Anti-Platelet Therapy Prior to Coronary Artery Bypass Graft Surgery
 |
 |
User Comments (0)
RSS Feeds